Cimilactone A

CAS No. 468733-06-4

Cimilactone A( ——— )

Catalog No. M39122 CAS No. 468733-06-4

Cimilactone A is a cycloartane-type triterpene glycoside. Cimilactone A can be isolated from the rhizomes of Cimicifuga foetida.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Cimilactone A
  • Note
    Research use only, not for human use.
  • Brief Description
    Cimilactone A is a cycloartane-type triterpene glycoside. Cimilactone A can be isolated from the rhizomes of Cimicifuga foetida.
  • Description
    Cimilactone A shows significant anticomplement activity (IC(50)= 28.6 microm).
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    468733-06-4
  • Formula Weight
    590.754
  • Molecular Formula
    C33H50O9
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Li-Rong Sun, et al. Cimicifoetisides A and B, two cytotoxic cycloartane triterpenoid glycosides from the rhizomes of Cimicifuga foetida, inhibit proliferation of cancer cells. Beilstein J Org Chem. 2007 Jan 31;3:3. ?
molnova catalog
related products
  • Ninerafaxstat

    Ninerafaxstat hifts cellular metabolism from fatty acid oxidation to glucose oxidation.Ninerafaxstat decreases fatty acid oxidation and improve overall mitochondrial respiration.Ninerafaxstat inhibit the growth and proliferation of cancer cells .

  • Orcinol gentiobiosid...

    Orcinol gentiobioside (compound 4) is a natural product isolated from the rhizomes of?C. breviscapa.

  • Clivatuzumab

    Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells.